DML. In early Nov I posted why I was buying AMRN . Last Friday I posted why I was selling half that Nov position ....I was up 80% which is fine with me . Tonite I’m trying to share what IMHO is the importance of Kaiser’s MITIGATE COVID trial . RAF provided the Twitter link
IF ....again ..IF , the interim data on this trial ....due late Feb / March indicates Vascepa is likely to reduce COVID hospitalization by those studied ( high risk CAD patients ) by more then 18% .....it will be the biggest thing since the Reduce It trial data release .....provided it’s confirmed in final analysis at the end of the trial . That is just my opinion Don’t know if it’s “ self serving “ or not . Do your own DD and make your own decision. This post is not intended as investment advice We clear now ? Kiwi
DML. Be fore warned. I’ll probably be writing some self serving posts on the MITIGATE trial later today .
I’ve decided to buy some AMRN late March and April call options on what I hope will be great interim results .
I’m not suggesting anyone do likewise. I usually lose buying options . My MITIGATE posts will be an endeavor to get others to find holes in my expectation that if interim is very positive it will be a game changer for AMRN
Feel free to challenge my MITIGATE hypothesis . I welcome opposing views Kiwi